Regeneron's Linvoseltamab Granted FDA Priority Review for Relapsed/Refractory Multiple Myeloma

The FDA assigned the biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma with a Prescription Drug User Fee Act of August 22, 2024.

Source link
#Regeneron039s #Linvoseltamab #Granted #FDA #Priority #Review #RelapsedRefractory #Multiple #Myeloma